COVID A
UTHORS
Online profiles of coronavirus experts
Return to Top
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19.
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-ß-1a and hydroxychloroquine in hospitalized patients with COVID-19. Clin Microbiol Infect. 2021 Dec; 27(12):1826-1837.
View in:
PubMed
subject areas
Adult
Antiviral Agents
Drug Combinations
Female
Humans
Hydroxychloroquine
Interferon beta-1a
Lopinavir
Male
Middle Aged
Ritonavir
Treatment Outcome
authors with profiles
Lionel Piroth
Florence Ader
Odile Launay
Nathan Peiffer-Smadja
Yazdan Yazdanpanah
France Mentré
Lila Bouadma
Valérie Pourcher
François Danion
Saad Nseir
Julien Poissy
Guillaume Martin-Blondel
Florent Wallet
Elisabeth Botelho-Nevers
Antoine Kimmoun
Karine Lacombe
François-Xavier Lescure
Claire Andrejak
Jean Reignier
Jean-Christophe Richard
Bruno Lina
Maude Bouscambert-Duchamp
Kevin Bouiller
Stéphane Jauréguiberry
Juliette Saillard
Axelle Dupont
Thérèse Staub
Violaine Tolsma
Gilles Peytavin
Bruno Mourvillier
Marion Noret
Alpha Diallo
Drifa Belhadi
Alain Makinson
Johan Courjon
Maya Hites
Dominique Costagliola
Sarah Gallien
Rostane Gaci
Emmanuel Faure
François Raffi
Jean-Christophe Navellou
Aline Dechanet
Clément Dubost
Charles Burdet
Sylvie Leroy
François Goehringer
Olivier Epaulard
Raphael Clere-Jehl
André Cabié
Minh Patrick Lê
Amandine Gagneux-Brunon
Noémie Mercier
Christelle Delmas
Joy Mootien
Toni Alfaiate
Jean-Philippe Lanoix
Jean Reuter